AI, Clean Energy & Health Stocks: The Big Winners in a Multipolar 2026Zacks Investment Research • 02/20/26
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.GlobeNewsWire • 02/17/26
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 02/16/26
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23GlobeNewsWire • 01/27/26
Strength Seen in Axsome (AXSM): Can Its 4.1% Jump Turn into More Strength?Zacks Investment Research • 01/21/26
Axsome Therapeutics Begins Phase III Study on AXS-14 for FibromyalgiaZacks Investment Research • 01/16/26
Why Axsome Therapeutics (AXSM) is a Top Momentum Stock for the Long-TermZacks Investment Research • 01/15/26
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product RevenueGlobeNewsWire • 01/12/26
AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's AgitationZacks Investment Research • 01/02/26
Axsome Therapeutics Stock Jumps After FDA Grants Priority Review For Alzheimer's Agitation DrugInvestors Business Daily • 12/31/25
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA SubmissionGlobeNewsWire • 12/31/25
Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference TranscriptSeeking Alpha • 12/04/25
Axsome (AXSM) Up 5.3% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/03/25